Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 191

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors

Open access
Haeusler, Rebecca A., Hartil, Kirsten, Vaitheesvaran, Bhavapriya, Arrieta-Cruz, Isabel, Knight, Colette M., Cook, Joshua R., Kammoun, Helene L., Febbraio, Mark A., Gutierrez-Juarez, Roger, Kurland, Irwin J., Accili, Domenico·2014·Nature Communications

Abstract

Insulin integrates hepatic glucose and lipid metabolism, directing nutrients to storage as glycogen and triglyceride. In type 2 diabetes, levels of the former are low and the latter are exaggerated, posing a pathophysiologic and therapeutic conundrum. A branching model of insulin signalling, with FoxO1 presiding over glucose production and Srebp-1c regulating lipogenesis, provides a potential explanation. Here we illustrate an alternative mechanism that integrates glucose production and lipogenesis under the unifying control of FoxO. Liver-specific ablation of three FoxOs (L–FoxO1,3,4) prevents the induction of glucose-6-phosphatase and the repression of glucokinase during fasting, thus increasing lipogenesis at the expense of glucose production. We document a similar pattern in the early phases of diet-induced insulin resistance, and propose that FoxOs are required to enable the liver to direct nutritionally derived carbons to glucose versus lipid metabolism. Our data underscore the heterogeneity of hepatic insulin resistance during progression from the metabolic syndrome to overt diabetes, and the conceptual challenge of designing therapies that curtail glucose production without promoting hepatic lipid accumulation. The transcription factors FoxoO1 and Srebp-1 control hepatic glucose and lipid production, respectively. Here, Haeusler et al.propose a model that integrates glucose and lipid regulation in the normal and diabetic liver under the unifying control of FoxO transcription factors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms6190

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 41

  1. Brown, M. S. & Goldstein, J. L. Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 7, 95–96 (2008). · DOI · Paper page
  2. Matsumoto, M., Pocai, A., Rossetti, L., Depinho, R. A. & Accili, D. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab. 6, 208–216 (2007). · DOI · Paper page
  3. Lu, M. et al. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat. Med. 18, 388–395 (2012). · DOI · Paper page
  4. Zhang, K. et al. Hepatic suppression of Foxo1 and Foxo3 causes hypoglycemia and hyperlipidemia in mice. Endocrinology 153, 631–646 (2012). · DOI · Paper page
  5. Haeusler, R. A., Kaestner, K. H. & Accili, D. FoxOs function synergistically to promote glucose production. J. Biol. Chem. 285, 35245–35248 (2010). · DOI · Paper page
  6. Porstmann, T. et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 8, 224–236 (2008). · DOI · Paper page
  7. Yecies, J. L. et al. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab. 14, 21–32 (2011). · DOI · Paper page
  8. Gershman, B. et al. High-resolution dynamics of the transcriptional response to nutrition in Drosophila: a key role for dFOXO. Physiol. Genomics 29, 24–34 (2007). · DOI · Paper page
  9. Haeusler, R. A., Pratt-Hyatt, M., Welch, C. L., Klaassen, C. D. & Accili, D. Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia. Cell Metab. 15, 65–74 (2012). · DOI
  10. Ido-Kitamura, Y. et al. Hepatic FoxO1 integrates glucose utilization and lipid synthesis through regulation of Chrebp O-glycosylation. PLoS ONE 7, e47231 (2012). · DOI
  11. Tao, R. et al. Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene. J. Biol. Chem. 286, 14681–14690 (2011). · DOI
  12. Zhang, W. et al. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J. Biol. Chem. 281, 10105–10117 (2006). · DOI · Paper page
  13. Haeusler, R. A., Han, S. & Accili, D. Hepatic FoxO1 ablation exacerbates lipid abnormalities during hyperglycemia. J. Biol. Chem. 285, 26861–26868 (2010). · DOI
  14. Samuel, V. T. et al. Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with Type 2 Diabetes. Proc. Natl Acad. Sci. USA 106, 12121–12126 (2009). · DOI · Paper page
  15. Xiong, X., Tao, R., DePinho, R. A. & Dong, X. C. Deletion of hepatic FoxO1/3/4 genes in mice significantly impacts on glucose metabolism through downregulation of gluconeogenesis and upregulation of glycolysis. PLoS ONE 8, e74340 (2013). · DOI
  16. Li, Y. & Mechin, M. C. & van de Werve, G. Diabetes affects similarly the catalytic subunit and putative glucose-6-phosphate translocase of glucose-6-phosphatase. J. Biol. Chem. 274, 33866–33868 (1999). · DOI
  17. Matschinsky, F. M. Assessing the potential of glucokinase activators in diabetes therapy. Nat. Rev. Drug Discov. 8, 399–416 (2009). · DOI · Paper page
  18. Velho, G. et al. Impaired hepatic glycogen synthesis in glucokinase-deficient (MODY-2) subjects. J. Clin. Invest. 98, 1755–1761 (1996). · DOI · Paper page
  19. Postic, C. et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J. Biol. Chem. 274, 305–315 (1999). · DOI · Paper page
  20. O’Doherty, R. M., Lehman, D. L., Telemaque-Potts, S. & Newgard, C. B. Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. Diabetes 48, 2022–2027 (1999). · DOI · Paper page
  21. Ferre, T., Riu, E., Bosch, F. & Valera, A. Evidence from transgenic mice that glucokinase is rate limiting for glucose utilization in the liver. FASEB J. 10, 1213–1218 (1996). · DOI · Paper page
  22. Grimsby, J. et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301, 370–373 (2003). · DOI · Paper page
  23. Lloyd, D. J. et al. Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors. Nature 504, 437–440 (2013). · DOI
  24. Pfefferkorn, J. A. et al. The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus. Bioorg. Med. Chem. Lett. 22, 7100–7105 (2012). · doi:10.1016/j.bmcl.2012.09.082
  25. Hirota, K. et al. A combination of HNF-4 and Foxo1 is required for reciprocal transcriptional regulation of glucokinase and glucose-6-phosphatase genes in response to fasting and feeding. J. Biol. Chem. 283, 32432–32441 (2008). · DOI
  26. Iynedjian, P. B., Ucla, C. & Mach, B. Molecular cloning of glucokinase cDNA. Developmental and dietary regulation of glucokinase mRNA in rat liver. J. Biol. Chem. 262, 6032–6038 (1987). · DOI
  27. Walker, D. G. & Holland, G. The development of hepatic glucokinase in the neonatal rat. Biochem. J. 97, 845–854 (1965). · doi:10.1042/bj0970845
  28. Bossard, P., Parsa, R., Decaux, J. F., Iynedjian, P. & Girard, J. Glucose administration induces the premature expression of liver glucokinase gene in newborn rats. Relation with DNase-I-hypersensitive sites. Eur. J. Biochem. 215, 883–892 (1993). · DOI
  29. Xu, J. et al. Decreased hepatic futile cycling compensates for increased glucose disposal in the Pten heterodeficient mouse. Diabetes 55, 3372–3380 (2006). · DOI
  30. Nissim, I. et al. Effects of a glucokinase activator on hepatic intermediary metabolism: study with 13C-isotopomer-based metabolomics. Biochem. J. 444, 537–551 (2012). · DOI
  31. Xu, J. et al. Determination of a glucose-dependent futile recycling rate constant from an intraperitoneal glucose tolerance test. Anal. Biochem. 315, 238–246 (2003). · DOI
  32. Ferre, T., Riu, E., Franckhauser, S., Agudo, J. & Bosch, F. Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance. Diabetologia 46, 1662–1668 (2003). · DOI
  33. Shimomura, I. et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell 6, 77–86 (2000). · doi:10.1016/s1097-2765(05)00010-9 · Paper page
  34. Qiang, L. & Accili, D. Uncoupling of acetylation from phosphorylation regulates FOXO1 function independent of its sub-cellular localization. J. Biol. Chem. 285, 27396–27401 (2010). · DOI · Paper page
  35. Kitamura, Y. I. et al. FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab. 2, 153–163 (2005). · DOI · Paper page
  36. Ozcan, L. et al. Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity. Cell Metab. 15, 739–751 (2012). · DOI · Paper page
  37. Monnier, L., Colette, C., Dunseath, G. J. & Owens, D. R. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 30, 263–269 (2007). · DOI · Paper page
  38. Okamoto, H., Obici, S., Accili, D. & Rossetti, L. Restoration of liver insulin signaling in Insr knockout mice fails to normalize hepatic insulin action. J. Clin. Invest. 115, 1314–1322 (2005). · doi:10.1172/jci200523096
  39. Haas, J. T. et al. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. Cell. Metab. 15, 873–884 (2012). · DOI · Paper page
  40. Vaitheesvaran, B. et al. Peripheral effects of FAAH deficiency on fuel and energy homeostasis: role of dysregulated lysine acetylation. PLoS ONE 7, e33717 (2012). · DOI
  41. Barber, M. N. et al. Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoS ONE 7, e41456 (2012). · DOI · Paper page

Cited by

See all 191

Metadata

Authors
Haeusler, R. A., Hartil, K., Vaitheesvaran, B., Arrieta-Cruz, I., Knight, C. M., Cook, J. R., Kammoun, H. L., Febbraio, M. A., Gutierrez-Juarez, R., Kurland, I. J., & Accili, D.
Venue
Nature Communications
Published
2014-10-13
Volume
5
Issue
1
Pages
5190-5190
ISSN
2041-1723 (ISSN-L)
OpenAlex
W1987734980
Cited by
191
References
6
FWCI
6.08
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.